Eric Rogier, Camelia Herman, Curtis S Huber, Karen E S Hamre, Baby Pierre, Kimberly E Mace, Jacquelin Présumé, Gina Mondélus, Ithamare Romilus, Tamara Elismé, Thomas P Eisele, Thomas Druetz, Alexandre Existe, Jacques Boncy, Jean F Lemoine, Venkatachalam Udhayakumar, Michelle A Chang
Haiti is striving for zero local malaria transmission by the year 2025. Chloroquine remains the first-line treatment, and sulfadoxine/pyrimethamine (SP) has been used for mass drug-administration pilot programs. In March 2016, nationwide molecular surveillance was initiated to assess molecular resistance signatures for chloroquine and SP. For 778 samples collected through December 2017, we used Sanger sequencing to investigate putative resistance markers to chloroquine (Pfcrt codons 72, 74, 75, and 76), sulfadoxine (Pfdhps codons 436, 437, 540, 581, 613), and pyrimethamine (Pfdhfr codons 50, 51, 59, 108, 164)...
May 2020: Emerging Infectious Diseases